Antibody Drug Conjugate News and Research

RSS
Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

Samplify Systems introduces 32-channel integrated ultrasound analog front-end receiver modules

Samplify Systems introduces 32-channel integrated ultrasound analog front-end receiver modules

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

USPTO issues patent related to Seattle Genetics' ADC technology

USPTO issues patent related to Seattle Genetics' ADC technology

DaVita's presentations at ADC: New developments in the field of CKD, Vascular Access and Home Modalities

DaVita's presentations at ADC: New developments in the field of CKD, Vascular Access and Home Modalities

Seattle Genetics generates $110M through ADC technology license agreements

Seattle Genetics generates $110M through ADC technology license agreements

Chemed announces financial results for fourth-quarter ended December 31, 2009

Chemed announces financial results for fourth-quarter ended December 31, 2009

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Global market for oncology drugs is forecast to reach $80 billion by 2050

Global market for oncology drugs is forecast to reach $80 billion by 2050

Seattle Genetics and GSK sign ADC collaboration agreement

Seattle Genetics and GSK sign ADC collaboration agreement

KarmelSonix selects Blackfin digital signal processors from Analog Devices

KarmelSonix selects Blackfin digital signal processors from Analog Devices

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.